Apogee Therapeutics, Inc. Common Stock annual free cash flow for fiscal TTM was -$235 million, a decrease of 0.9% from -$233 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($235M) | ($233M) | ($172M) | ($75M) | ($16M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($71M) | ($56M) | ($63M) | ($54M) | ($63M) | ($53M) | ($68M) | ($43M) | ($29M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More APGE metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All APGE financial statements → Interactive APGE charts →
About TickerBase · Data methodology & sources · Privacy · Terms